BMS acquires MyoKardia, maker of drugs for cardiovascular disease, for $13.1B October 6, 2020 Auto Bot BioPharma, biopharma nl, Bristol-Myers Squibb, cardiovascular disease, hypertrophic cardiomyopathy, M&A, mavacamten, MyoKardia, New York 0 The companies expect the deal to close in the fourth quarter. MyoKardia’s lead drug candidate is mavacamten, which it is developing for hypertrophic cardiomyopathy and plans to submit to the FDA in the first quarter of next year.